[Correspondence] PSMA-TTV as a point-of-care selector

In The Lancet Oncology, Louise Emmett and colleagues1 present an elegant prespecified substudy from the ENZA-p trial that shows that baseline prostate-specific membrane antigen (PSMA)-PET total tumour volume (PSMA-TTV) is not only prognostic for overall survival, but also predictive of benefit from adding [177Lu]Lu-PSMA-617 to enzalutamide as a first-line treatment in patients with high-risk, metastatic castration-resistant prostate cancer. However, whole-body standardised uptake value (SUV) mean did not show predictive value in this combination setting.